^
Association details:
| Biomarker: | AGK-BRAF fusion |
|---|---|
| Cancer: | Melanoma |
| Drug: | Ojemda (tovorafenib) (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical Activity of the Type II Pan-RAF Inhibitor Tovorafenib in BRAF-Fusion Melanoma
Published date:
04/20/2023
Excerpt:
Patient 1 is a 53-year-old Asian male with AGK-BRAF fusion, Stage III non-Spitzoid cutaneous melanoma who had undergone multiple lymphadenectomies and skin lesion excision surgery...Following tovorafenib treatment, he had a complete response at the 8-week scan, which was confirmed at 16 weeks...Early results from the first three patients of this ongoing trial showed tovorafenib is generally well tolerated and has encouraging antitumor activity in BRAF-fusion melanoma.
